P
VRTX icon

&Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

&Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.5M Buy
23,387
+1,249
+6% +$582K 0.05% 310
2025
Q4 		$10M Sell
22,138
-5,811
-21% -$2.5M 0.05% 314
2025
Q3 		$8.16M Buy
27,949
+2,809
+11% +$1.17M 0.05% 314
2025
Q2 		$11.2M Buy
25,140
+11,187
+80% +$5.16M 0.09% 220
2025
Q1 		$6.88M Buy
13,953
+881
+7% +$411K 0.07% 242
2024
Q4 		$5.33M Buy
13,072
+6,948
+113% +$3.22M 0.06% 268
2024
Q3 		$2.85M Buy
6,124
+4,220
+222% +$2.03M 0.06% 298
2024
Q2 		$893K Buy
+1,904
New +$826K 0.04% 382

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

&Partners's VRTX Position: Q1 2026 in Review

&Partners increased its Vertex Pharmaceuticals (VRTX) stake by 5.6% in Q1 2026, buying an estimated $582K and bringing the position to 23,387 shares worth $10.5M. The position accounts for 0.05% of the portfolio, ranked #310.

&Partners first reported a position in VRTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $11.2M in Q2 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • &Partners held 23,387 shares of Vertex Pharmaceuticals worth $10.5M as of Q1 2026.
  • &Partners bought 1,249 Vertex Pharmaceuticals shares in Q1 2026, an estimated $582K.
  • Vertex Pharmaceuticals made up 0.05% of &Partners's portfolio in Q1 2026, its #310 holding.
  • &Partners first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • &Partners's Vertex Pharmaceuticals position peaked at $11.2M in Q2 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.